{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T02:29:58Z","timestamp":1769653798152,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100032579","name":"Beijing Medical Award Foundation","doi-asserted-by":"publisher","award":["YXJX-2022-0435-0372"],"award-info":[{"award-number":["YXJX-2022-0435-0372"]}],"id":[{"id":"10.13039\/100032579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2023-17-3"],"award-info":[{"award-number":["320.6750.2023-17-3"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.lfs.2026.124218","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:37:22Z","timestamp":1768894642000},"page":"124218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Endostar overcomes Osimertinib-resistance mediated EGFR-activation mutation, T790M and cis-C797S triple mutations via enhancing the binding of Osimertinib to EGFR protein"],"prefix":"10.1016","volume":"388","author":[{"given":"Zhongquan","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhua","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2026.124218_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2026.124218_bb0010","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40265-018-0916-4","article-title":"Targeting EGFR in lung cancer: current standards and developments","volume":"78","author":"D\u00edaz-Serrano","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2026.124218_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000060","article-title":"Mechanisms of resistance to EGFR-targeted drugs: lung cancer","volume":"1","author":"Morgillo","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.lfs.2026.124218_bb0020","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2026.124218_bb0025","doi-asserted-by":"crossref","first-page":"ix177","DOI":"10.1093\/annonc\/mdy483.007","article-title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","volume":"29","author":"Cho","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2026.124218_bb0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","article-title":"Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib","volume":"19","author":"Rotow","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2026.124218_bb0035","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.jtho.2017.06.017","article-title":"Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance","volume":"12","author":"Wang","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2026.124218_bb0040","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/j.jtho.2019.04.020","article-title":"Durable clinical response of lung adenocarcinoma harboring EGFR 19Del\/T790M\/in trans-C797S to combination therapy of first- and third-generation EGFR tyrosine kinase inhibitors","volume":"14","author":"Zhou","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2026.124218_bb0045","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jtho.2020.04.014","article-title":"Effective treatment of lung adenocarcinoma harboring EGFR-activating mutation, T790M, and cis-C797S triple mutations by brigatinib and cetuximab combination therapy","volume":"15","author":"Wang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2026.124218_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2026.124218_bb0055","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1158\/1078-0432.CCR-22-3901","article-title":"BBT-176, a novel fourth-generation tyrosine kinase inhibitor for osimertinib-resistant EGFR mutations in non\u2013small cell lung cancer","volume":"29","author":"Lim","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2026.124218_bb0060","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241280689","article-title":"BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer","volume":"16","author":"Lim","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lfs.2026.124218_bb0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","article-title":"EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lfs.2026.124218_bb0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2026.124218_bb0075","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2026.124218_bb0080","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lfs.2026.124218_bb0085","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2026.124218_bb0090","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.21037\/atm-22-6101","article-title":"Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study","volume":"10","author":"Long","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.lfs.2026.124218_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106668","article-title":"Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET\/MYC\/AXL axis","volume":"188","author":"Lei","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2026.124218_bb0100","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.2147\/OTT.S298655","article-title":"Combination of osimertinib and anlotinib may overcome the resistance mediated by in EGFR\/T790M\/cis-C797S in NSCLC: a case report","volume":"14","author":"Zhou","year":"2021","journal-title":"OTT"},{"key":"10.1016\/j.lfs.2026.124218_bb0105","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1111\/1759-7714.14603","article-title":"The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non-small cell lung cancer: a real-world study","volume":"13","author":"Feng","year":"2022","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.lfs.2026.124218_bb0110","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/37126","article-title":"Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance","volume":"390","author":"Boehm","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2026.124218_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129575","article-title":"Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutation","volume":"98","author":"Kageji","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.lfs.2026.124218_bb0120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lfs.2026.124218_bb0125","first-page":"377","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.lfs.2026.124218_bb0130","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.2147\/OTT.S114722","article-title":"Osimertinib making a breakthrough in lung cancer targeted therapy","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.lfs.2026.124218_bb0135","first-page":"2422","article-title":"Endostatin\u2019s emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications","volume":"2015","author":"Walia","year":"1850","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.lfs.2026.124218_bb0140","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ctrv.2013.11.009","article-title":"Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents","volume":"40","author":"Limaverde-Sousa","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lfs.2026.124218_bb0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"FLAURA investigators, overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2026.124218_bb0150","doi-asserted-by":"crossref","first-page":"S1668","DOI":"10.1016\/j.annonc.2023.10.591","article-title":"512MO FLAURA2: safety and CNS outcomes of first-line (1L) osimertinib (osi) \u00b1 chemotherapy (CTx) in EGFRm advanced NSCLC","volume":"34","author":"Planchard","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2026.124218_bb0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/08977190802312844","article-title":"EGFR family: structure physiology signalling and therapeutic targets","volume":"26","author":"Burgess","year":"2008","journal-title":"Growth Factors"},{"key":"10.1016\/j.lfs.2026.124218_bb0160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40487-017-0055-1","article-title":"Current status and study progress of recombinant human endostatin in cancer treatment","volume":"6","author":"Li","year":"2018","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.lfs.2026.124218_bb0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.radonc.2018.10.032","article-title":"HELPER study: a phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer","volume":"131","author":"Zhai","year":"2019","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.lfs.2026.124218_bb0170","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/oncolo\/oyab078","article-title":"Rh-endostatin plus irinotecan\/cisplatin as second-line therapy for advanced esophageal squamous cell carcinoma: an open-label, phase II study","volume":"27","author":"Hu","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.lfs.2026.124218_bb0175","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1186\/s12885-020-07527-4","article-title":"Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lfs.2026.124218_bb0180","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00280-014-2656-9","article-title":"Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial","volume":"75","author":"Chen","year":"2015","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:22:00Z","timestamp":1769610120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320526000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"alternative-id":["S0024320526000263"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124218","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endostar overcomes Osimertinib-resistance mediated EGFR-activation mutation, T790M and cis-C797S triple mutations via enhancing the binding of Osimertinib to EGFR protein","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124218"}}